Supplementary Figure 1.

Published: 23 September 2025| Version 1 | DOI: 10.17632/8dvd29djtd.1
Contributors:
Christine Olagun-Samuel, Christine Akoh, Nnaemeka Anyanwu, Elizabeth Sher, Carli Needle, Jamie Widawsky, David Cohen, Emily Milam , Alexandra Flamm, Vikash Oza, Theodora Karagounis

Description

Tralokinumab for Moderate-to-Severe Atopic Dermatitis: A Viable Option for Dupilumab Non-Responders

Files

Categories

Atopic Dermatitis

Licence